Critical Survey: Compugen (CGEN) versus Vaxart (VXRT)

Compugen (NASDAQ:CGEN) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, badyst recommendations, profitability, institutional ownership, valuation, risk and dividends.

Profitability

This table compares Compugen and Vaxart’s net margins, return on equity and return on badets.

Institutional & Insider Ownership

20.6% of Compugen shares are held by institutional investors. Comparatively, 7.6% of Vaxart shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Comparatively, 44.8% of Vaxart shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Compugen and Vaxart’s top-line revenue, earnings per share (EPS) and valuation.

Vaxart has higher revenue and earnings than Compugen.

Volatility and Risk

Compugen has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Compugen and Vaxart, as reported by MarketBeat.

Compugen currently has a consensus price target of $9.00, suggesting a potential upside of 171.90%. Given Compugen’s stronger consensus rating and higher probable upside, research badysts plainly believe Compugen is more favorable than Vaxart.

Summary

Compugen beats Vaxart on 8 of the 12 factors compared between the two stocks.

About Compugen

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company’s therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company’s pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. has a clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb’s programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. The company was incorporated in 1993 and is headquartered in Holon, Israel.

About Vaxart

Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company’s platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.

Receive News & Ratings for Compugen Daily – Enter your email address below to receive a concise daily summary of the latest news and badysts’ ratings for Compugen and related companies with MarketBeat.com’s FREE daily email newsletter.